Market access and commercialisation strategies should always be considered as early as possible in the product development process to increase the likelihood of a successful drug launch.
This is even more important when developing treatments for rare or orphan diseases, for which having a patient doesn’t actually guarantee that your product will enter the market and be paid for.
There is a lot of work to be done to build disease state awareness, generate data to demonstrate value and develop brand positioning. You’ll be up against treatments for a whole range of diseases, all competing for the same budget or funding. To ensure your product has the best chance of entering the market, you’ll need to start planning early.
To read the full article, click here.